The prognostic role of the class III β-tubulin in Non-Small Cell Lung Cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: A meta-analysis

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Yang, Yan Long ^a   Luo, Xiu Ping ^a   Xian, Lei ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; BETA TUBULIN 3; CARBOPLATIN; CISPLATIN; DOCETAXEL; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; TAXANE; TAXOID; TUBULIN; VINBLASTINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; DISEASE ASSOCIATION; EVENT FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; METABOLISM; MORTALITY; PROGNOSIS; PUBLISHING; RISK; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; ODDS RATIO; PROGNOSIS; PUBLICATION BIAS; TAXOIDS; TREATMENT OUTCOME; TUBULIN; VINBLASTINE;

EID: 84899075841     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093997     Document Type: Article

References (57)

1. International Agency for Research on Cancer, W.H.O (2010) The GLOBO-CAN Project. Available: http://globocan.iarc.fr.(accessed 2012 Oct 12).
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
3. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, et al. (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220-241.
4. Guilbert JJ (2003) The world health report 2002 - reducing risks, promoting healthy life. Educ Health (Abingdon) 16: 230.
5. Non-small Cell Lung Cancer Collaborative G (2000) Chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev: CD002139.
6. Stewart DJ (2010) Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 75: 173-234.
7. Custodio AB, Gonzalez-Larriba JL, Bobokova J, Calles A, Alvarez R, et al. (2009) Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. J Thorac Oncol 4: 891-910.
8. Chiou JF, Liang JA, Hsu WH, Wang JJ, Ho ST, et al. (2003) Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung 181: 267-273.
9. Yared JA, Tkaczuk KH (2012) Update on taxane development: new analogs and new formulations. Drug Des Devel Ther 6: 371-384.
10. Galano G, Caputo M, Tecce MF, Capasso A (2011) Efficacy and tolerability of vinorelbine in the cancer therapy. Curr Drug Saf 6: 185-193.
11. Felip E, Gridelli C, Baas P, Rosell R, Stahel R, et al. (2011) Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 22: 1507-1519.
12. Seve P, Dumontet C (2008) Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9: 168-175. (Pubitemid 351150128)
13. Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, et al. (2006) Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 12: 2774-2779.
14. Tommasi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, et al. (2007) Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer 120: 2078-2085. (Pubitemid 46555844)
15. Urano N, Fujiwara Y, Doki Y, Kim SJ, Miyoshi Y, et al. (2006) Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 28: 375-381.
16. Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, et al. (2003) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22: 3548-3553. (Pubitemid 36765314)
17. Seve P, Isaac S, Tredan O, Souquet PJ, Pacheco Y, et al. (2005) Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11: 5481-5486. (Pubitemid 41060824)
18. Dumontet C, Isaac S, Souquet PJ, Bejui-Thivolet F, Pacheco Y, et al. (2005) Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92: E25-30.
19. Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, et al. (2005) Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4: 2001-2007. (Pubitemid 43056983)
20. Seve P, Lai R, Ding K, Winton T, Butts C, et al. (2007) Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 13: 994-999. (Pubitemid 46340378)
21. Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, et al. (2008) Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 62: 105-112.
22. Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, et al. (2009) Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64: 326-333.
23. Azuma K, Sasada T, Kawahara A, Hattori S, Kinoshita T, et al. (2009) Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol 64: 565-573.
24. Ikeda S, Takabe K, Suzuki K (2009) Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathol Int 59: 863-867.
25. Huang CL, Kadota K, Liu D, Ueno M, Nakasima N, et al. (2010) Expression of ERCC1 and class III beta-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane. Exp Ther Med 1: 445-451.
26. Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, et al. (2010) The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 68: 478-483.
27. Vilmar AC, Santoni-Rugiu E, Sorensen JB (2011) Class III beta-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial. Clin Cancer Res 17: 5205-5214.
28. Reiman T, Lai R, Veillard AS, Paris E, Soria JC, et al. (2012) Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol 23: 86-93.
29. Christoph DC, Kasper S, Gauler TC, Loesch C, Engelhard M, et al. (2012) betaV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer. Br J Cancer 107: 823-830.
30. Krawczyk P, Kowalski DM, Wojas-Krawczyk K, Mlak R, Jaskiewicz P, et al. (2012) The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors. Chemotherapy 58: 60-69.
31. Kaira K, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, et al. (2013) The role of betaIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. Int J Clin Oncol 18: 371-379.
32. Jiang H, Yu XM, Zhou XM, Wang XH, Su D (2013) Correlation between microtubule-associated gene expression and chemosensitivity of patients with stage II non-small cell lung cancer. Exp Ther Med 5: 1506-1510.
33. Zhang Y, Yang H, Liu J, Deng Q, He P, et al. (2013) High expression levels of class III beta-tubulin in resected non-small cell lung cancer patients are predictive of improved patient survival after vinorelbine-based adjuvant chemotherapy. Oncol Lett 6: 220-226.
34. Xiao YY, Song Y, Shi Y (2009) ERCC1 and class III beta-tubulin protein expression in relation to tumor and survival of stage IIIB/IV NSCLC patients treated with TP/NP chemotherapy regimens. Chin J Lung Cancer 12: 14-16.
35. Yang JQ, Wang BH, Liu HX (2009) Relationship between expression of III-tubulin, stathmin and drug resistance to taxane in local advanced non-small cell lung cancer. Chin Clin Oncol 14: 884-889.
36. Pu X, Wang J, Xu L, Ma J, Wang Z, et al. (2009) [Relationship between Expression of beta-tubulin-III Plus Stathmin in Advanced Non-Small Cell Lung Cancer and its Sensitivity to Venorelbine Chemotherapy.]. Zhongguo Fei Ai Za Zhi 12: 49-53.
37. Gong J, Liu ZL, Ha MW (2009) Expression of β-tubulin III and Bc-l2 and the clinical significance in non-small cell lung cancer. Chinese Journal of New Drugs 18: 815-818.
38. Wan YY, Hui HX, Wang XW, Sun SA, Wu J (2011) [The correlation between chemotherapeutic efficacy and breast cancer susceptibility gene 1 and class IIIbeta-tubulin protein expression in non-small cell lung cancer patients]. Zhonghua Nei Ke Za Zhi 50: 469-473.
39. Guo HQ, Zhao Y (2011) Relationship betwwen the expression level of βIII-tubulin and p53 and chemosensistivity of paclitaxel in advanced and local advanced NSCLC. Oncology Progress 9: 420-423.
40. Zhou ZS, Liao XF, Zhen QH, He HJ (2012) Expresion of Survivin BRCA1 and class IIIb-tubulin in non-small cell lung cancer and its relationship with resistance to paclitaxel. Journal of Chinese Oncology 18: 806-810.
41. Zhang JP, Hu XL, Li GF, Chen RB (2012) Relationship between expression of b-tubulin-III and drug efficacy of paclitaxel in non-small cell lung cancer. Medical Recapitulate 18: 2637-2638.
42. Gao LH, Mao GX (2012) The relationship between b-tubulin III expression in tumor cells and chemotherapy sensitivity of patients with NSCLC receiving paclitaxel Journal of Nantong University(Medical Sciences) 32: 188-190.
43. Liu P, Wang HX, Wang HL (2013) Relationship betweenb-tubulin expression and paclitaxel containing regimen with drug resistance in non small cell lung cancer. Journal of Clinical Medicine in Practice 17: 12-15.
44. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, et al. (2003) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: http://wwwohrica/programs/ clinicalepidemiology/ oxfordasp (accessed 2012 May 5).
45. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
46. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214. (Pubitemid 11167383)
47. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
48. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. (Pubitemid 37088507)
49. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
50. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. (Pubitemid 17189972)
51. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
52. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. (Pubitemid 27387172)
53. Ikeda N, Nagase S, Ohira T (2009) Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers. Ann Thorac Cardiovasc Surg 15: 144-149.
54. Zhang HL, Ruan L, Zheng LM, Whyte D, Tzeng CM, et al. (2012) Association between class III beta-tubulin expression and response to paclitaxel/ vinorebinebased chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 77: 9-15.
55. Oye RK, Shapiro MF (1984) Reporting results from chemotherapy trials. Does response make a difference in patient survival? JAMA 252: 2722-2725. (Pubitemid 15200143)
56. Dumontet C, Sikic BI (1999) Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17: 1061-1070. (Pubitemid 29109340)
57. Dumontet C, Jordan MA, Lee FF (2009) Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 8: 17-25.